Topical Insulin for Glaucoma (TING2)
Starting soon · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
In brief
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.
Key facts
- Study ID
- NCT07619482
- Run by
- Stanford University
- People needed
- 90
- Starts
- 2026-06-01
- Expected to finish
- 2029-10-01
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Byers Eye Institute at Stanford University — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.